Canoa ProSolus Press Release

Canoa Inc. to Acquire Privately-Held ProSolus Inc., Accelerating Transdermal Patch Drug Delivery Product Development

MIAMI, Florida, August 02, 2019 – Canoa Inc. (“Canoa”), a Delaware corporation with a focus on healthcare and pharmaceuticals, today announced that it has agreed to acquire ProSolus® Inc. (“ProSolus”), from Mission Pharmacal® Company, in an all-cash transaction. ProSolus is a private pharmaceutical company with an expertise in transdermal drug delivery systems. “This transaction will…

pharmaceutical coater

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery Technology

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery Technology Parent company, Mission Pharmacal, expands commitment to patch technology with significant investments in manufacturing and commercial team. Transdermal patch production line at ProSolus, Inc. in Miami Juan Mantelle, ProSolus Chief Operating Officer and Chief Scientific Officer Download Press Release MIAMI, Fla. (April 25, 2017) – ProSolus,…

Prosolus pharmaceuticals

Mission Pharmacal Acquires ProSolus Pharmaceuticals

Acquisition adds cutting-edge expertise in transdermal drug development and manufacturing SAN ANTONIO, TX — Effective May 29, 2015, Mission Pharmacal Company (“Mission”) has acquired the assets of ProSolus Pharmaceuticals LP headquartered in Miami, Fla. Mission’s wholly-owned subsidiary, ProSolus Inc., offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal (through the skin) drug…



ProSolus, Inc. is proud to announce the upcoming launch of LidoFlex, developed in conjunction with Mission Pharmacal and Richmar. LidoFlex has a 4% Lidocaine concentration, which is the highest concentration available without a prescription. For more information about the product, or if you are a healthcare practitioner interested in LidoFlex, click here.